Document is current
Any future updates will be listed below
-
Authors
Wander, Connor M.
Tsujimoto, Tamy Harumy Moraes
Ervin, John F.
Wang, Chanung
Maranto, Spencer M.
Bhat, Vanya
Dallmeier, Julian D.
Wang, Shih-Hsiu Jerry
Lin, Feng-Chang
Scott, William K.
Holtzman, David M.
Cohen, Todd J. http://orcid.org/0000-0002-4099-0278
-
Funding
Funding for this research was provided by:
NIH/NIA (R01AG061188, R01AG066871)
National Center for Advancing Translational Sciences (UL1TR001111)
NIH (P30AG072958, P30NS045892, RF1AG047644)
NIH Blueprint for Neuroscience Research (U54HD079124, RF1NS090934)
JPB Foundation (-)
- License Information
-
More Information
Article History
Received: 9 May 2022
Accepted: 16 July 2022
First Online: 8 August 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee.
: Informed consent was obtained from all individual participants included in the study and according to institutional procedures for autopsy consents for post‑mortem tissue.
: C.M.W. is employed by Alkahest, Inc. D.M.H. is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali and Cajal Neuroscience and consults for Genentech and Alector.
